SRR8518424
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.320
- PROTEIN_SECRETION+0.320
- CHOLESTEROL_HOMEOSTASIS+0.280
- E2F_TARGETS+0.280
- MTORC1_SIGNALING+0.260
- MYC_TARGETS_V2+0.260
- OXIDATIVE_PHOSPHORYLATION+0.240
- G2M_CHECKPOINT+0.220
- MYC_TARGETS_V1+0.220
- ESTROGEN_RESPONSE_LATE+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.460
- INFLAMMATORY_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.280
- IL2_STAT5_SIGNALING-0.250
- COMPLEMENT-0.210
- APOPTOSIS-0.170
- HEDGEHOG_SIGNALING-0.160
- WNT_BETA_CATENIN_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5903549 | — | cohortA4 | 0.896 |
| 2 | TCGA-AR-A1AS-01A-11R-A12P-07 | — | B | 0.869 |
| 3 | SRR4296106 | — | cohortSQ1 | 0.862 |
| 4 | SRR8518327 | — | E | 0.850 |
| 5 | SRR8518238 | — | C | 0.832 |
| 6 | SRR25617914 | — | C | 0.831 |
| 7 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.830 |
| 8 | TCGA-E2-A14V-01A-11R-A12D-07 | — | C | 0.829 |
| 9 | SRR12696752 | — | — | 0.828 |
| 10 | 97591eeb-89dc-4b70-92d4-2bb70d263098 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |